Literature DB >> 18156365

P-glycoprotein: so many ways to turn it on.

Richard Callaghan1, Emily Crowley, Simon Potter, Ian D Kerr.   

Abstract

Expression of the ABC transporter P-glycoprotein (P-gp or ABCB1) is associated with resistance to chemotherapy in cancer. However, early investigations into the regulation of ABCB1 expression revealed that the process is not a classical induction as observed for certain metabolizing enzymes. The process involves the cellular stress response pathway initiated by either inflicted (e.g., chemotherapy damage) or endogenous (e.g., hypoxia) factors. However, ABCB1 is also expressed in a number of noncancerous tissues. In particular, the protein is found at tissues providing a barrier or secretory function. The localization of ABCB1 in normal tissues will impact significantly on drug pharmacokinetics, in particular the absorption and elimination processes. This review also describes the mechanism underlying ABCB1 expression in noncancerous tissue, a process that does not involve the stress response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18156365     DOI: 10.1177/0091270007311568

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  40 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

2.  Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel.

Authors:  Ravi S Kasinathan; William M Morgan; Robert M Greenberg
Journal:  Mol Biochem Parasitol       Date:  2010-05-12       Impact factor: 1.759

3.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 4.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

5.  Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.

Authors:  Jean-Pierre Gillet; Junbai Wang; Anna Maria Calcagno; Lisa J Green; Sudhir Varma; Mari Bunkholt Elstrand; Claes G Trope; Suresh V Ambudkar; Ben Davidson; Michael M Gottesman
Journal:  Mol Pharm       Date:  2011-07-15       Impact factor: 4.939

Review 6.  Drug interactions in childhood cancer.

Authors:  Cyrine Haidar; Sima Jeha
Journal:  Lancet Oncol       Date:  2010-09-22       Impact factor: 41.316

Review 7.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

Review 8.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Authors:  King Leung Fung; Michael M Gottesman
Journal:  Biochim Biophys Acta       Date:  2009-03-11

9.  Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.

Authors:  Rocío Núñez-Torres; Miguel Martín; Jose Ángel García-Sáenz; María Rodrigo-Faus; María Del Monte-Millán; Hugo Tejera-Pérez; Guillermo Pita; Julio C de la Torre-Montero; Karen Pinilla; Belén Herraez; Lorena Peiró-Chova; Begoña Bermejo; Anna Lluch; Anna González-Neira
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

10.  Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus.

Authors:  Amit Kansal; Deepak Tripathi; Mohit K Rai; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2015-09-29       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.